CDC Hantavirus Study and Ebola Concerns Boost Demand for TOMI’s Disinfection Tech
Event summary
- CDC study finds 30% of rodents in U.S. agricultural regions exposed to hantavirus, 10% actively infected.
- Ebola outbreak in Central Africa escalates, raising demand for scalable decontamination solutions.
- TOMI’s SteraMist platform highlighted for its role in containing past Ebola outbreaks with WHO and USAID.
- SteraMist uses ionized hydrogen peroxide (iHP) for rapid, high-level environmental decontamination.
- TOMI targets hospitals, hotels, airports, and industrial facilities with its disinfection technology.
The big picture
TOMI’s SteraMist platform is gaining strategic relevance as global pathogen threats intensify. The CDC’s hantavirus findings and the Ebola crisis underscore the need for advanced decontamination solutions in healthcare, agriculture, and industrial settings. TOMI’s past success in containing Ebola outbreaks positions it as a key player in the growing market for high-level disinfection technologies.
What we're watching
- Market Expansion
- How the CDC study and Ebola concerns will accelerate adoption of SteraMist in high-risk sectors.
- Regulatory Dynamics
- Whether heightened pathogen risks will lead to stricter decontamination standards for facilities.
- Execution Risk
- The pace at which TOMI can scale production and deployment to meet rising global demand.
Related topics